Fizazi, et al. ARAMIS: Efficacy and safety of darolutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC). ASCO-GU 2019, abstract 140.
Boosten maakt lagere dosering olaparib mogelijk
apr 2024 | Borstkanker, Gynaecologische oncologie, Uro-oncologie